Pfizer Inc. (PFE) Stock Price & Analysis
Pfizer Inc. (PFE) closed at USD 30.42 on Thursday, October 22, 2026, up 1.91% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 29.85; the Oct 22, 2026 session ranged USD 29.88–30.44 on volume of 28,682,254 shares. Market capitalization is $173.38B, with a 52-week range of USD 23.62–30.44 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PFE.md
Key facts (PFE)
- Last four reported quarters (through Jun 28, 2026): revenue $63.7B, net income $4.33B (6.8% margin), free cash flow $11.0B (SEC filings).
- Valuation: P/E 40.0x (avg 38.2x at the last 3 fiscal year-ends), net debt $54.8B.
- Earnings quality: non-operating income -$9.61B (gains on equity investments $182M) vs operating income null over the last four quarters; P/E excluding non-operating income ≈12.4x (estimate: non-operating income taxed at the company's 0% effective rate).
- 10 of 80 tracked superinvestors hold PFE (13F, Q2 2026): 1 new, 5 added, 3 reduced, 1 unchanged.
- Total return with dividends: 1Y +32.0% vs S&P 500 +14.9%; 5Y -8.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.73, revenue estimate $15.9B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PFE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $81.3B | $101B | $59.6B | $63.6B | $62.6B | $63.7B |
| Gross profit | $50.5B | $66.8B | $34.6B | $45.8B | $46.5B | — |
| Net income | $22.0B | $31.4B | $2.12B | $8.03B | $7.77B | $4.33B |
| EPS (diluted) | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 | — |
| Free cash flow | $29.9B | $26.0B | $4.79B | $9.84B | $9.07B | $11.0B |
| Gross margin | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% | — |
| Net margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% | 6.8% |
| Revenue growth | +95.2% | +24.5% | -41.1% | +6.8% | -1.6% | — |
| Cash + short-term investments | $24.0B | $19.2B | $7.25B | $11.9B | $10.3B | — |
| Total debt | $37.8B | $35.4B | $63.8B | $61.2B | $64.6B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 28, 2026) (PFE)
P/E 40.0x · P/E ex non-operating (est.) ≈12.4x · P/S 2.7x · EV/Sales 3.6x · P/FCF 15.8x · P/B 2.0x · FCF yield 6.34% · Earnings yield 2.50% · Net debt $54.8B · EV $228B
P/E at fiscal year-ends: Dec 2025 18.3x, Dec 2024 18.8x, Dec 2023 77.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (PFE)
10 of 80 tracked investors hold PFE. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 3.04% | $4.2M | Reduced -7.1% |
| Harry Burn | Sound Shore | 2.83% | $92.0M | Added +33.1% |
| Torray Funds | 2.79% | $20.7M | Added +10.7% | |
| Kahn Brothers | Kahn Brothers Group | 2.41% | $13.6M | Unchanged |
| Prem Watsa | Fairfax Financial Holdings | 0.95% | $25.1M | Added +5.3% |
| Sarah Ketterer | Causeway Capital Management | 0.50% | $46.2M | Added +0.1% |
| Richard Pzena | Pzena Investment Management | 0.42% | $143M | Added +0.6% |
| Bruce Berkowitz | Fairholme Capital | 0.37% | $5.6M | New position |
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.6M | Reduced -5.8% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $2.1M | Reduced -0.8% |
Analysts (PFE)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | JP Morgan | Target raised | Neutral | $28 → $30 |
| 2026-10-08 | Cantor Fitzgerald | Target raised | Neutral | $27 → $28 |
| 2026-10-06 | Scotiabank | Target raised | Sector Outperform | $30 → $33 |
| 2026-09-10 | HSBC | Target raised | Hold | $28 → $30 |
| 2026-08-07 | Guggenheim | Target lowered | Buy | $35 → $31 |
| 2026-07-13 | BMO Capital | Target lowered | Outperform | $34 → $30 |
| 2026-07-13 | Guggenheim | Target lowered | Buy | $36 → $35 |
| 2026-07-10 | B of A Securities | Target lowered | Neutral | $27 → $26 |
| 2026-07-08 | JP Morgan | Target lowered | Neutral | $30 → $28 |
| 2026-07-06 | Cantor Fitzgerald | Reiterated | Neutral | $27 |
| 2026-07-06 | HSBC | Downgrade | Buy → Hold | $32 → $28 |
Total return (dividends reinvested) (PFE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +32.0% | -8.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +32.1% | -1.7% |
| Volatility (annualized) | 21.1% | 25.0% |
| Max drawdown | -15.7% (Apr 2026→Jun 2026) | -57.1% (Dec 2021→Apr 2025) |
PFE revenue by product line (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $11.86B | 78.9% | -0.8% |
| Royalty | $474.0M | 3.2% | +11.3% |
| Pfizer CentreOne | $373.0M | 2.5% | +7.2% |
| Total revenue | $15.03B | 100% | — |
PFE revenue by region (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $8.86B | 58.9% | -0.4% |
| International Developed Markets | $3.74B | 24.9% | +10.3% |
| International Emerging Markets | $2.43B | 16.2% | +2.9% |
| Total revenue | $15.03B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PFE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | “(b)Emblaveo is being developed in collaboration with AbbVie.” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name PFE in their SEC reports
| Relationship to PFE | Company | Filing | Sentence |
|---|---|---|---|
| partner | Neuphoria Therapeutics Inc. (NEUP) | 10-K Sep 18, 2026 | “Each CVR represents a contractual right to receive a pro rata share of CVR payments, if any, equal to 100% of the net proceeds actually received by Parent or its affiliates (i) under the Company's research collaboration and license agreement with Merck Sharp & Dohme Corp. for a period of 15 years from Completion; (ii) under the Participants Agreement and associated CRC Commercialization License Agreements (includi…” |
| competitor | iBio, Inc. (IBIO) | 10-K Aug 28, 2026 | “Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC), Johnson & Johnson, Pfizer Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech, Inc. (a member …” |
| partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | 20-F Jun 17, 2026 | “•ADCETRIS: We entered into a Collaboration Agreement with Pfizer Inc. ("Pfizer") (as successor in interest to Seagen, Inc., which was acquired by Pfizer in December 2023) in 2009 for the global co-development of ADCETRIS and its commercialization around the world (other than the U.S. and Canada, where ADCETRIS is commercialized by Pfizer).” |
| partner | Roivant Sciences Ltd. (ROIV) | 10-K May 20, 2026 | “License and Collaboration Agreement with Pfizer, Inc.” |
| partner | ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) | 20-F Apr 29, 2026 | “a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer, and research” |
| competitor | GeoVax Labs, Inc. (GOVX) | 10-K Apr 15, 2026 | “We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical companies including Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, and Pfizer; mid-size pharmaceutical companies and emerging biotechnology companies including Dynavax, Novavax, Moderna, BioNTech and Bavarian Nordic; and academic and not-for-profit vaccine researchers and devel…” |
| competitor | IRIDEX CORP (IRIX) | 10-K Apr 2, 2026 | “Some of our principal pharmaceutical competitors are Alcon, Inc., Allergan, Inc., Astellas Pharma Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Roche Holding Ltd. (Genentech).” |
| partner | MANGOCEUTICALS, INC. (MGRX) | 10-K Apr 1, 2026 | “branded drugs like Viagra (Pfizer) and Cialis (marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation)” |
| competitor | Alaunos Therapeutics, Inc. (TCRT) | 10-K Mar 31, 2026 | “Key competitors in the obesity space include (but are not limited to) companies such as Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics, and others.” |
| competitor | Alvotech (ALVO) | 20-F Mar 31, 2026 | “For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz; in the market for AVT04, our biosimilar to Stelara (ustekinumab), we compete against Janssen (the originator), Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bio…” |
| partner | LeonaBio, Inc. (LONA) | 10-K Mar 31, 2026 | “Lasofoxifene was discovered through a research collaboration between Pfizer Inc. ("Pfizer") and Ligand Pharmaceuticals ("Ligand").” |
| supplier | TOMI Environmental Solutions, Inc. (TOMZ) | 10-K Mar 31, 2026 | “On August 12, 2025, we announced a major new customer in the eye health sector, comparable in scale to Pfizer and Merck, who implemented SteraMist iHP at two facilities in under four months and placed open BIT Solution orders for 2026.” |
| competitor | Curanex Pharmaceuticals Inc (CURX) | 10-K Mar 30, 2026 | “of our competitors have far greater marketing and research capabilities than us, such as Regeneron/Sanofi, Pfizer, LEO Pharma, Eli Lilly,” |
| partner | Allarity Therapeutics, Inc. (ALLR) | 10-K Mar 30, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” |
| partner | HYPERION DEFI, INC. (HYPD) | 10-K Mar 30, 2026 | “Bringing to DRL her legacy of creating transformative partnerships with leading sports and technology brands, Ms. Jacobson forged groundbreaking partnerships with organizations including Algorand, Google, T-Mobile, New Balance, the U.S. Air Force, Pfizer and others.” |
PFE customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (25%, 16%, 13%) of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name them.
PFE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.73 | $0.82 | -10.7% | $15.88B | 19 |
| Next quarter (ends Dec 2026) | $0.71 | $0.70 | +0.8% | $16.89B | 17 |
| Current fiscal year (ends Dec 2026) | $2.96 | $2.95 | +0.3% | $62.22B | 24 |
| Next fiscal year (ends Dec 2027) | $2.88 | $2.83 | +2.0% | $59.89B | 22 |
PFE options: expected move
Options price a move of about ±5.8% (±$1.76) by Nov 6, 2026, which includes earnings on Nov 3, 2026; the earnings reaction alone is priced at about ±3.3%. Over the last 8 reports the stock moved ±1.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 25.0% | ±3.0% |
| Nov 6, 2026 | 14 | 31.7% | ±5.8% |
| Nov 13, 2026 | 21 | 28.3% | ±5.9% |
| Nov 20, 2026 | 28 | 26.1% | ±6.1% |
| Nov 27, 2026 | 35 | 26.1% | ±6.6% |
| Dec 4, 2026 | 42 | 25.9% | ±7.1% |
| Dec 18, 2026 | 56 | 26.0% | ±8.1% |
| Jan 15, 2027 | 84 | 24.8% | ±9.5% |
30-day implied volatility 26.5% vs 16.7% realized over the last 30 trading days. Put/call ratio (volume) 0.47. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 30.42 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 29.85 |
| Open | USD 30.05 |
| Day Range | USD 29.88 – 30.44 |
| 52-Week Range | USD 23.62 – 30.44 |
| Volume | 28,682,254 shares |
| Market Cap | $173.38B |
| Exchange | NYQ |
Technical Analysis (PFE)
Nexqual's technical model rates PFE "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.77 (overbought) |
| vs SMA50 | Above (USD 28.23) |
| MACD | 0.58 (positive) |
Earnings (PFE)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.73 |
| Revenue Estimate | $15.88B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.77 vs est 0.68 ▲ beat |
| 2026-03-31 | USD 0.75 vs est 0.72 ▲ beat |
| 2025-12-31 | USD 0.66 vs est 0.57 ▲ beat |
| 2025-09-30 | USD 0.87 vs est 0.63 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (PFE)
| Total Revenue | $63.70B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.60% |
| Gross Margin | +74.72% |
| Operating Margin | +27.88% |
| Profit Margin | +6.80% |
| ROE | +5.01% |
| Debt / Equity | 0.74 |
| Current Ratio | 1.27 |
| Total Cash | $11.70B |
| Total Debt | $63.48B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $10.98B (17.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financial Health Score (PFE)
Nexqual rates Pfizer Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:21 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 28% (last 12 months) |
| Balance Sheet | Solid — $8.26B cash and investments vs $63.1B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $11.0B (last 4 quarters to Jun 2026, SEC), 17% margin |
| Efficiency | Mixed — ROE 5%, ROA 5.8% |
Ownership (PFE)
| Insider Ownership | +0.10% |
|---|---|
| Institutional Ownership | +69.05% |
| Shares Outstanding | 5.70B |
| Float | 5.69B |
| Short % of Float | +2.64% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (PFE)
Pfizer Inc. is led by Albert Bourla D.V.M., Chairman of the Board & CEO, per Nexqual as of October 23, 2026 at 09:21 UTC.
| Chairman of the Board & CEO | Albert Bourla D.V.M. |
|---|---|
| Chief Scientific Officer and President of Research & Development | Chris Boshoff FMedSci |
| Interim CFO & Executive VP | Cecile Guegan |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | Michael S. Vincent |
Major Backers & Investors (PFE)
Notable institutional backers of Pfizer Inc. include Fisher Asset Management, LLC, Morgan Stanley, Fidelity, according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fisher Asset Management, LLC | 1.91% |
| Morgan Stanley | 1.69% |
| Fidelity | 1.3% |
| NORGES BANK | 1.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.29% |
| Vanguard Group | 8.62% |
| State Street | 5.39% |
| Geode Capital | 2.37% |
| Northern Trust | 1.04% |
| BNY Mellon | 1.02% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Pfizer Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, approximately $500 million of R&D savings achieved from our ongoing realigning our cost base program in 2025 is expected to be reinvested in R&D programs in 2026.
- Revenues from operations outside the U.S. of $25.5 billion, $24.9 billion and $31.4 billion accounted for 41%, 39% and 53% of Total revenues in 2025, 2024 and 2023, respectively.
- Ono has exclusive rights to commercialize the product in Japan and South Korea, Medison Pharma Ltd. has exclusive rights to commercialize the product in Israel and Pierre Fabre has exclusive rights to commercialize the product in all other countries, including Europe and Asia (excluding Japan and South Korea).
- Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with our R&D focus areas.
Partnerships
- Outside the U.S., Pfizer has commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa. (14)Product not yet approved or authorized in this market. (15)Ngenla is licensed from OPKO Health, Inc., and is developed and commercialized by Pfizer, including in the U.S., Latin America, Europe, Africa, and Asia. (16)Tivdak is commercialized in collaboration with Genmab.
- Takeda has commercialization rights in the rest of the world and pays Pfizer a royalty based on a percentage of Takeda's net sales of Adcetris in its licensed territories, based on annual net sales tiers. •Tivdak (tisotumab vedotin-tftv) is commercialized in collaboration with Genmab.
Legal & Regulatory Risks (Item 1A, quoted)
- Any additional reduction of U.S. federal spending on entitlement programs beyond the IRA, including Medicare, Medicaid, or any other publicly funded or subsidized health programs, and the 340B Program, may affect payment for our products or services provided using our products.
- We expect additional drug cost containment efforts at both the federal and state levels, as evidenced by the MFN Initiatives and the December 2025 issue by HHS of proposed rules for mandatory CMMI pilots which could require additional price concessions.
- The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years and have high costs.
- We may have difficulties recruiting and enrolling patients for clinical trials on a consistent basis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt